The metabotropic glutamate receptor 5 (mGlu5) is a glutamateactivated class C G protein-coupled receptor widely expressed in the central nervous system and clinically investigated as a drug target for a range of indications, including depression, Parkinson's disease, and fragile X syndrome. Here, we present the novel potent, selective, and orally bioavailable mGlu5 negative allosteric modulator with inverse agonist properties 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP). CTEP binds mGlu5 with low nanomolar affinity and shows Ͼ1000-fold selectivity when tested against 103 targets, including all known mGlu receptors. CTEP penetrates the brain with a brain/plasma ratio of 2.6 and displaces the tracer [ 3 H]3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-methyl-oxime (ABP688) in vivo in mice from brain regions expressing mGlu5 with an average ED 50 equivalent to a drug concentration of 77.5 ng/g in brain tissue. This novel mGlu5 inhibitor is active in the stress-induced hyperthermia procedure in mice and the Vogel conflict drinking test in rats with minimal effective doses of 0.1 and 0.3 mg/kg, respectively, reflecting a 30-to 100-fold higher in vivo potency compared with 2-methyl-6-(phenylethynyl)pyridine (MPEP) and fenobam. CTEP is the first reported mGlu5 inhibitor with both long half-life of approximately 18 h and high oral bioavailability allowing chronic treatment with continuous receptor blockade with one dose every 48 h in adult and newborn animals. By enabling long-term treatment through a wide age range, CTEP allows the exploration of the full therapeutic potential of mGlu5 inhibitors for indications requiring chronic receptor inhibition.
Introduction
Glutamate is the predominant excitatory neurotransmitter in the central nervous system (CNS) involved in vital brain functions such as cognition, learning and memory, processing of emotions, and motor control. Glutamatergic neurotransmission is mediated by two types of receptors: 1) the ionotropic glutamate receptors, which are nonselective cation channels subdivided by their respective agonists into N-methyl-D-aspartate (NMDA), ␣-amino-3-hydroxy-5-methy-4-isoxazoleproprionic acid (AMPA), and 2-carboxyl-3-carboxymethyl-4-isopropenylpyrrolidine (kainate) receptors; and 2) the metabotropic glutamate (mGlu) receptors 1 to 8, which are G protein-coupled receptors modulating synaptic function (Kew and Kemp, 2005) . The mGlu5 receptor is a class C G protein-coupled receptor coupling to Gq-type G proteins, and its signal transduction is mediated mainly by the activation of phospholipase C␤, intracellular release of inositol phosphates and Ca 2ϩ and the activation of protein kinase C and mitogen-activated kinase. In the native tissue context, numerous protein-protein interactions with other receptors, scaffolding, and cytoplasmic proteins add complexity to the signal transduction of mGlu5 (Bockaert et al., 2010; Ribeiro et al., 2010) . In the CNS the mGlu5 receptor is expressed in the limbic cortex, hippocampus, amygdala, thalamus, olfactory tubercle, and basal ganglia (Spooren et al., 2003) . In neurons, mGlu5 is found primarily postsynaptically in excitatory terminals often colocalized with adenosine A 2a , dopamine D 2 , and NMDA receptors. In addition, mGlu5 is expressed in astrocytes where its function is not yet fully resolved (Hamilton and Attwell, 2010) .
The pharmacological toolset for investigating mGlu5 receptor function was initially limited to amino acid-like orthosteric agonists and antagonists with unsatisfactory selectivity, potency, and brain penetration, which were restricted primarily to in vitro use (Kew and Kemp, 2005) . The discovery of potent and systemically active mGlu5-negative allosteric modulators such as 2-methyl-6-(phenylethynyl)pyridine (MPEP) (Gasparini et al., 1999) , 3-((2-methyl-4-thiazolyl) ethynyl)pyridine (MTEP) (Cosford et al., 2003) , and fenobam (N-(3-chlorophenyl)-NЈ-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea triggered intense research addressing the therapeutic potential of mGlu5. Preclinical studies largely generated with these prototypical mGlu5 inhibitors support mGlu5 as a drug target and have translated into drug development programs in a wide range of indications including anxiety and depression, Parkinson's disease, pain, addiction, Huntington's disease, and fragile X syndrome (Gasparini et al., 2008 ; for review, see Jaeschke et al., 2008) . The prototypical mGlu5 inhibitors are invaluable research tools, which, however, have limitations for in vivo use because of their low metabolic stability translating into short half-lives. Especially for chronic in vivo experiments requiring sustained receptor blockade, the need for several daily drug administrations presents logistical challenges, can confound phenotypes of animal models and behavioral tests, and is not feasible, e.g., when working with newborn animals or fragile transgenic mouse lines. The in vivo use of fenobam is limited by an extensive metabolism (Wu et al., 1995) leading to variable exposure and possibly producing pharmacologically active metabolites . For MPEP, a weak inhibition of the norepinephrine transporter (Heidbreder et al., 2003) , weak activities on NR2B-containing NMDA receptors and monoamine oxidase A (Lea and Faden, 2006) , and positive allosteric modulation of mGlu4 (Mathiesen et al., 2003) have been reported.
Here is described the pharmacological profile of the novel potent, selective, and orally bioavailable mGlu5 negative allosteric modulator with inverse agonist activity 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl) ethynyl)pyridine) (CTEP). The new mGlu5 inhibitor binds human, mouse, and rat mGlu5 with high affinity and low species difference (K d ϭ 1.7, 1.8, and 1.5 nM for human, mouse, and rat mGlu5, respectively). The high affinity translates into 30-to 100-fold higher in vivo potency compared with MPEP and fenobam in two rodent behavioral models sensitive to antianxiety drugs. CTEP is Ͼ1000-fold selective for mGlu5 when tested on 103 molecular targets, including all known mGlu receptors. The unique feature of CTEP is its pharmacokinetic profile characterized by a brain/plasma (B/P) ratio of 2.6 and a high oral bioavailability of approximately 100%. The compound can be dosed orally, intraperitoneally, or subcutaneously formulated in a simple microsuspension. With its long half-life of approximately 18 h in mice, CTEP enables chronic dosing with sustained receptor blockade with one dose every 48 h.
Materials and Methods

Materials
CTEP (RO4956371), MPEP, MTEP, and fenobam were synthesized at F. Hoffmann-La Roche Ltd. The tracer [ 3 H]3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-methyl-oxime (ABP688) was synthesized essentially as described previously , I-Bolton Huntersubstance P). All other drugs, chemicals, and enzymes were purchased at the highest purity available from Tocris Bioscience (Bristol, UK), Sigma Chemie (Buchs, Switzerland), Roche Applied Sciences (Rotkreuz, Switzerland), GE Healthcare, and Thermo Fischer Scientific (Wohlen, Switzerland). Cell culture reagents were purchased from Invitrogen (Basel, Switzerland), cell culture plastic ware was purchased from Nunc (Langenselbold, Germany), and all other plastic ware and consumables were purchased from BD Biosciences (Allschwil, Switzerland), Eppendorf AG (Basel, Switzerland), Greiner Bio-One GmbH (Frickenhausen, Germany), Hamamatsu Corporation (Solothurn, Switzerland), Rainin Instruments (Greifensee, Switzerland), and Semadeni (Ostermundigen, Switzerland). For in vitro radioligand binding assays, membranes isolated from HEK293 cells transiently (A 1 , A 3 , D 1 , mGlu3, mGlu5a, SERT, NET, DAT, and NK 1-3 ) or stably (GABA A ␣ 5 ␤ 3 ␥ 2 , SERT, NET, and DAT) transfected with plasmids encoding the respective receptors or receptor subunit combinations (GABA A and ␣ 5 ␤ 3 ␥ 2 ) were used. Cell culture and transfections were performed essentially as described previously ) . Cell membranes were prepared from cells harvested 48 h after transfection. The cells were washed three times in cold phosphate-buffered saline, suspended in cold homogenization buffer (50 mM Tris-HCl and 10 mM EDTA, pH 7.4), and homogenized with a polytron (Kinematica AG, Basel, Switzerland) for 10 s at 10,000 rpm. The pellet obtained after centrifugation for 30 min at 48,000g at 4°C was resuspended in homogenization buffer containing 10 mM Tris-HCl and 0.1 mM EDTA, homogenized, and centrifuged as above, and the resulting pellet was resuspended in a small volume of homogenization buffer. The protein content of the membrane suspension was determined with the Bradford method (Bio-Rad Laboratories, Reinach, Switzerland) using ␥-globulin as standard, and aliquots of the membrane preparation were stored at Ϫ80°C. Membranes from cortex tissue dissected from Wistar rat brain were prepared following essentially the same procedure as described for cells.
Plasmids, Cell Culture, and Membrane Preparations
In Vitro Pharmacology
Radioligand Binding. For all filtration radioligand binding assays, membrane preparations expressing the target receptors or receptor combinations were resuspended in radioligand binding buffer (15 mM Tris-HCl, 120 mM NaCl, 5 mM KCl, 1.25 mM CaCl 2 , and 1.25 mM MgCl 2 , pH 7.4), and the membrane suspension was mixed with the appropriate concentrations of radioligand and nonlabeled drugs in 96-well plates in a total volume of 200 l and incubated for 60 min at the appropriate temperature. At the end of the incubation, membranes were filtered onto Whatman (Clifton, NJ) Unifilter (96-well microplate with bonded GF/C filters) preincubated with 0.1% polyethyleneimine in wash buffer (50 mM Tris-HCl, pH 7.4) with a Filtermate 196 harvester (PerkinElmer) and washed three times with ice-cold wash buffer. Radioactivity captured on the filter was quantified on a Topcount microplate scintillation counter (PerkinElmer) with quenching correction after the addition of 45 l of MicroScint 40 per well and shaking for 20 min. The concentration of membranes and incubation time was determined for each assay in pilot experiments. Radioligand binding assays on SERT, NET, and DAT (Tatsumi et al., 1997; Liu et al., 2009 ) and the A 1 adenosine receptor were performed using the scintillation proximity assay principle (Bosworth and Towers, 1989) . Selectivity screening at CEREP (Poitiers, France) ( Table 2 ) was conducted at a concentration of 1 M in duplicate for each target except for kainate glutamate receptors, L-type Ca 2ϩ channel (dihydropyridine site), and Na 2ϩ channel, which were examined in a dose-response manner up to a concentration of 10 M. Assay conditions for binding experiments are summarized in Supplemental Table S1 .
For competition binding experiments the concentration of radioligands was adjusted according to pilot experiments (Supplemental , human mGlu5a, rat mGlu5a, and mGlu8) or transiently (mouse mGlu5a) transfected with plasmids encoding the respective target receptor or with a combination of the target receptor and G␣15 (mGlu8) or G␣16 (mGlu2) were used. Cells were seeded at 5 ϫ 10 4 cells/well in poly-D-lysine-coated, 96-well, black/clear-bottomed plates. After 24 h, the cells were loaded for 1 h at 37°C with 2.5 M Fluo-4 acetoxymethyl ester in loading buffer (1ϫ Hanks' balanced salt solution and 20 mM HEPES). The cells were washed five times with loading buffer to remove excess dye, and intracellular calcium mobilization (intracellular calcium concentration) was measured using a FDSS7000 device (Hamamatsu).
The potency of CTEP and, where available, reference antagonists were studied in the presence of an agonist [mGlu1 and mGlu2, glutamate; mGlu5, quisqualate; mGlu8, (2S)-2-amino-4-phosphonobutanoic acid (L-AP4)] at a concentration triggering 60 to 80% of the maximal agonist response, which was determined daily in a separate experiment. The antagonists were applied in a serial dilution with 10 different concentrations 30 min before the application of agonists; potential agonist activities of CTEP were monitored on-line during the 5-to 30-min preincubation period (data not shown). Responses were measured as peak increase in fluorescence recorded after the addition of CTEP and reference antagonists (testing for agonist activity), as well as after the addition of agonist (testing for antagonist activity), minus basal (i.e., fluorescence without addition of agonist), normalized to the maximal stimulatory effect induced by a saturating concentration of the agonist measured on the same plate. Inhibition curves were fitted using XLfit according to the Hill equation y ϭ 100/(1 ϩ (x/ IC 50 )nH), where nH is the slope factor.
Inositol Phosphate Accumulation Assay. For inositol phosphate (IP) accumulation assays, HEK293 cells stably (human and rat mGlu5) or transiently (mouse mGlu5) transfected with plasmids encoding the respective target receptor were transfected with excitatory amino acid transporter 1 and seeded in poly-D-lysine-coated 96-well plates at a density of 80,000 cells/well in an inositol/glutamate-free Dulbecco's Modified Eagle's Medium with 10% dialyzed fetal bovine serum, 1% penicillin/streptomycin, 1 mM glutamate, and 5 Ci/ml myo-[ 2-3 H]inositol. After 24 h, cells were washed three times with washing buffer containing 1ϫ Hanks' balanced salt solution and 20 mM HEPES and incubated in the presence of glutamate pyruvate transaminase (Roche Applied Science, Indianapolis, IN) and sodium pyruvate for 1 h before the addition of agonists or antagonists in assay buffer (washing buffer containing 8 mM LiCl). After 45-min incubation with the agonist, the assay was terminated by the aspiration of the assay buffer and the lysis of cells with the addition of 100 l 20 mM formic acid per well. After 20-min incubation, a 20-l aliquot of the lysate was mixed with 80 l of RNA binding yttrium silicate bead suspension that bound to the inositol 35 S]GTP␥S, and L-AP4 at a concentration triggering 60 to 80% of the maximal agonist response, and 1 mg/well wheat germ agglutinin SPA beads. The plates were incubated for 30 min at room temperature under mild shaking, centrifuged for 3 min at 1000g, and counted immediately in a Topcount microplate scintillation counter (PerkinElmer). Data subtracted with the background (reaction with no agonist or drug in presence of 10 M cold GTP␥S) were normalized to the maximal stimulatory effect induced by a saturating concentration of L-AP4 measured on the same plate. 
N.A.D., no activity detected; N.S., nonselective; h, human; r, rat; b, bovine; p, porcine.
a Data generated at F. Hoffmann-La Roche Ltd. b Data generated at CEREP.
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cAMP Accumulation Assay. For the mGlu7a cAMP accumulation assay, a clonal CHO cell line deficient in dihydrofolate reductase activity (CHO-dhfr Ϫ ), harboring a luciferase reporter gene under the control of 5 cAMP-responsive elements (CHO-DUKX-CRE-luci cells) and stably transfected with mGlu7a was used. Cells were seeded at 5 ϫ 10 4 cells/well in poly-D-lysine coated, 96-well, black/clear-bottomed plates. After 24 h the growth medium [Dulbecco's Modified Eagle's Medium, 7.5% heat-inactivated fetal bovine serum, 1ϫ hypoxanthine/thymidine supplement, 0.2 mg/ml hygromycin, 0.4 mg/ml (2R,3S,4R,5R,6S)-5-amino-6-[(1R,2S,3S,4R,6S)-4,6-diamino-3-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-methylaminooxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-2-(1-hydroxyethyl)oxane-3,4-diol (G418), 1 mM L-glutamate, and 0.34 mM L-proline] was replaced with 1 mM 3-isobutyl-1-methylxanthine in Krebs Ringer bicarbonate buffer, and the plates were incubated for 60 min at 30°C. After adding CTEP in a serial dilution with nine different concentrations, plates were incubated for 15 min at 30°C, then forskolin and L-AP4 were added at final concentrations of 3 M and 3 mM, respectively, and plates were incubated for 30 min at 30°C. The cAMP detection was performed with the cAMP-Nano-TRF detection assay (Roche Applied Science) according to the manufacturer's instructions. Data subtracted with the background (reaction with no drug and no forskolin and L-AP4) were normalized to the maximal stimulatory effect induced by L-AP4 in the presence of 3 M forskolin.
Selectivity Testing at CEREP. CTEP's selectivity for mGlu5 was assessed at CEREP using the Diversity Profile panel at a concentration of 1 M in duplicates. Targets showing an effects size of Ͼ20% control were retested in a dose-response fashion at CEREP or F. Hoffmann-La Roche Ltd. (Table 2 ). Key experimental conditions used in the selectivity profiling of CTEP are summarized in Supplemental Table S1 .
Behavioral Pharmacology
Animals and Drug Treatment. All experiments with animals were conducted in accordance with federal and local regulations and with the approval of the City of Basel Animal Protection Committee.
Adult male Sprague-Dawley rats (body weight approximately 180 -210 g) and male NMRI mice (body weight approximately 25 g) were supplied by Charles River (Sulzfeld, Germany). Rats were group-housed and mice were-single housed in separate holding rooms at controlled temperature (20 -22°C) and 12-h light/dark cycle (lights on 6:00 AM). Animals were allowed ad libitum access to food and water, with the exception of those used in the Vogel conflict drinking test, where access to water was limited during the training sessions as described below. All formulations were prepared immediately before use in vehicle, consisting of 0.9% NaCl (w/v) and 0.3% Tween 80 (v/v) solution for oral administration of CTEP, MPEP, MTEP, and fenobam; 0.9% NaCl solution for MPEP and MTEP intravenously; and 30% N-methylpyrrolidone, 42% hydroxypropyl-␥-cyclodextrin, and 28% water for fenobam intravenously. The volume of administration for oral dosing was 5 ml/kg for rats, 10 ml/kg for mice, and 2.5 ml/kg for intravenous applications and 10 ml/kg for subcutaneous applications in mice.
Microsuspensions of CTEP, MPEP, MTEP, and fenobam were prepared by milling the compounds in the appropriate vehicle in a planetary ball mill (Retsch GmbH, Haan, Germany) with glass beads for 90 min. The resulting suspension was vacuum-filtered through a 100-m filter, adjusted to the final concentration, and stored frozen in aliquots at Ϫ80°C before use.
SIH in Mice. The SIH test was essentially performed as described previously . In brief, drug-naive, single-housed (Makrolon cage, 26 ϫ 21 ϫ 14 cm) male NMRI mice were used, and body temperature was measured twice in each mouse 1 min apart (T1 and T2, respectively). T1 served as the handling stressor, and the resulting increase in body temperature (⌬T ϭ T2 Ϫ T1) reflected the SIH. Mice were administered drug or vehicle orally 60 min before measuring T1.
Vogel Conflict Drinking in Rats. Male Sprague-Dawley rats were water-restricted for three consecutive 24-h periods. At the end of the first 24-h period, animals were allowed access to water in their home cage for 60 min. At the end of the second 24-h period, they were placed into the test chamber containing a drinking bottle and were allowed to drink freely for 15 min. Subsequently they received drinking water in their home cage for another 60 min. The drinking time in the test chamber was used to randomize the animals over the different treatments. The drinking time measured by an optical sensor was determined as the time spent by the rat at the drinking spout. At the end of the third 24-h period, rats were administered the experimental compounds or vehicle orally and isolated in a holding chamber until testing 60 min later. During the 10-min test period, they were allowed to drink freely for a cumulative time of 5 s, after which drinking was associated with an electric stimulus. That is, an electrical shock between the grid floor and the drinking spout (0.5 mA; 250 ms) was triggered every second of cumulative drinking time. This shock level strongly suppresses drinking to approximately 10% of normal levels.
Statistical Analysis of Behavioral Data. Statistical analyses were performed using Statistica (StatSoft, Hamburg, Germany). SIH data were statistically evaluated using a Dunnett multiple comparison test (two-tailed) after one-way analysis of variance. For the Vogel conflict drinking procedure, drinking time was analyzed by Mann-Whitney U post hoc tests. In all experiments, the level of significance was p Ͻ 0.05. For uniformity, all data are plotted as mean Ϯ S.E.M. in the figures.
Pharmacokinetics, In Vivo Binding, and Physicochemical Properties
Pharmacokinetics. For blood sample collection from adult mice, two consecutive blood samples were collected from each animal. The number of adult animals used per dose and route was typically five to seven (two analyzed samples for each data point). The recorded plasma profiles therefore represent composite profiles generated from several animals per compound and administration route. For newborn mice, only brain tissue was analyzed (one pooled sample from three to four animals per time point). Brain/plasma ratios for MPEP, MTEP, and fenobam were analyzed 1 h after a single oral dose of 30 mg/kg in adult mice.
For preparation of plasma samples approximately 1 ml of blood was collected into EDTA-coated 1.5-ml Eppendorf tubes and centrifuged for 5 min at 5000g, and the clear supernatant was transferred into a clean tube. Before analysis, 50 l of plasma samples were mixed with 150 l of acetonitrile containing the internal standard bosentan (200 ng/ml) in a 96-deep-well plate for protein precipitation. After centrifugation at 5900g for 10 min at room temperature, 100 l of supernatant was mixed with 100 l of water. From the above plasma extracts, 10 l were subjected to HPLC/MS analysis.
Brain samples were homogenized in three volumes (w/v) of water in a planetary ball mill (Retsch GmbH) with ceramic beads and then diluted with one volume of brain homogenate from drug-naive animals of the same species and age. From this homogenate 50 l were mixed with 150 l of acetonitrile containing the internal standard bosentan (200 ng/ml) for protein precipitation. After centrifugation at 5900g for 10 min at room temperature, 100 l of supernatant was mixed with 100 l of water. From the above plasma extracts, 10 l were subjected to HPLC/MS analysis.
Samples were analyzed using a combined HPLC/MS method. Standard solutions for the unknown compounds (CTEP, MPEP, MTEP, and fenobam), as well as the internal standard bosentan, were freshly prepared for each analysis. Solutions of unknown compounds in DMSO were serially diluted in DMSO to concentrations of 12.5 to 125,000 ng/ml and mixed 1:50 with plasma and brain extracts derived from drug-naive animals. A stock solution of bosentan in DMSO at a concentration of 1 mg/ml was diluted 1:5 in methanol.
Chromatographic analyses were performed using a Phenomenex (Torrance, CA) Luna C18 (50 ϫ 1.0 mm) 5.0-m, 100A analytical column at 70°C. The flow rate was 600 l/min. A 15-l mixing at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Downloaded from chamber was used to mix the mobile phase, which was a mixture of solvents A (10 mM ammonium acetate and 0.05% v/v formic acid in water) and B (acetonitrile containing, 0.05% v/v formic acid). The chromatography gradient for 2.5-min analytical runs is shown in Table 1 .
Chromatography eluates were analyzed using a heated TurboIonSpray mass spectrometer (AB SCIEX; Brugg, Switzerland). The gas used was nitrogen with the following settings: 50.00 for the nebulizing gas, 50.00 for the auxiliary gas, and 20.00 for the curtain gas. The ion spray was set at 5500 V, the declustering potential was at 121 V, and the entrance potential was at 10 V. The dwell time was 150 ms, and the temperature of the heated nebulizer temperature was 400°C. The mass spectrometer was programmed to admit protonated molecules [MϩH] ϩ at m/z 392.03 (I) and 552.24 (II) via the first quadripole filter (Q1), with collision-induced fragmentation at Q2 (collision gas nitrogen, setting CAD 10.00), and monitoring the product ions via Q3 at m/z 136.10 (I) and 202.20 (II). Peak area ratios obtained from selective reaction monitoring of analytes (m/z 392.03 Ͼ 128.10)/(m/z 552.24 Ͼ 202.20) were used for the construction of the calibration curve, using weighed (1/x) regression of the plasma concentrations and the measured peak area ratios. Data collection, peak integration, and calculations were performed using Analyst 1.5 PE-Sciex software (Applied Biosystems, Foster City, CA).
Microsomal clearance was determined essentially as described previously (Kuhlmann et al., 2010) .
In Vivo Receptor Occupancy Measurement. Adult male C57BL/6 mice (approximately 30 g body weight) received oral doses of vehicle or CTEP in a range of 0.01 to 3.0 mg/kg 90 min before a tail vein injection of 0.3 mCi/kg [ 3 H]ABP688 (specific activity: 80 Ci/ mmol) formulated in 28% (w/v) N-methyl pyrrolidone in 0.9% (w/v) saline containing Յ2% (w/v) ethanol. After 30 min mice were sacrificed, plasma samples were collected as described above, and brains were removed. From each animal, half of the brain was immediately frozen on dry ice for histology and autoradiography, the remaining half was used for analysis of drug exposure. Parasagittal brain sections were cut at 10-m thickness on a Leica CM1950 cryostat (Leica Microsystems, Nunningen, Switzerland), collected on Superfrost plus glass slides (Menzel, Braunschweig, Germany), air-dried, exposed for 5 days on [ 3 H]-sensitive phosphorimaging plates (GE Healthcare), and analyzed on an ImageQuant phosphorimager (GE Healthcare). Autoradiograms were analyzed using ImageQuant TL software (GE Healthcare). Selected brain regions were manually defined based on stereotactical information (Paxinos and Franklin, 2003) , and radioactivity bound in these regions was quantified. Using the radioactivity obtained in animals treated with vehicle and 3 mg/kg of CTEP as total and nonspecific binding, IC 50 values based on drug exposure were calculated using XLfit software as described for radioligand binding.
Measurement of Physicochemical Properties. The octanol/water distribution coefficient was determined as described previously (Kansy et al., 1998) . The plasma protein binding of drugs was determined as described previously (Banker et al., 2003; Wan and Holmen, 2009) .
Results
Discovery of CTEP. CTEP (C 19 H 13 ON 3 F 3 Cl; molecular weight ϭ 391.78) (Fig. 1 ) was discovered in a medicinal chemistry effort at F. Hoffmann-La Roche Ltd. starting from a high-throughput screen of a small molecular weight compound library based on a Ca 2ϩ mobilization assay using human mGlu5. The high-throughput screen delivered several hits from different chemical series including known mGlu5 antagonists comprised in the compound library such as MPEP, MTEP, and fenobam (Fig. 1) , as well as compounds starting from which CTEP was discovered.
CTEP Potently Binds mGlu5 with Small Species Differences. The in vitro binding properties of CTEP were characterized by saturation analyses of [ 3 H]CTEP on membranes from HEK293 cells expressing human, mouse, and rat mGlu5. The saturation isotherms were monophasic at a concentration range of 0.12 to 140 nM [ 3 H]CTEP and fitted best with a one-site model (Fig. 2, a-c). [ 3 H]CTEP binds to human, mouse, and rat mGlu5 with a dissociation constant (K d ) of 1.7, 1.8, and 1.5 nM, respectively ( Fig. 3b; Table 3 ). In the [ 3 H]IP accumulation assay, CTEP inhibits the constitutive activity of human mGlu5 by approximately 50% with an IC 50 of 40.1 nM (Fig. 4a) , demonstrating inverse agonist activity as reported previously for MPEP and fenobam . It is noteworthy that orthosteric antagonists such as (S)-4-carboxyphenylglycine do not show inverse agonist activity .
The mode of action of CTEP was further tested by recording concentration-response curves for quisqualate-induced [ 3 H]IP accumulation in the presence of various concentrations of CTEP. Increasing concentrations of CTEP trigger a right shift of the quisqualate concentration-response curve with a simultaneous reduction of the maximal response amplitude (Fig. 4b) , which is indicative of an allosteric mode of action. This observation is in line with the lack of displacement of [ 3 H]CTEP by orthosteric mGlu5 ligands. CTEP Is Highly Selective for mGlu5. The selectivity of CTEP with respect to other mGlu receptors was assessed for mGlu1, mGlu2, and mGlu8 with Ca 2ϩ mobilization assays (Fig. 5, a, b, and g ), for mGlu3 with a (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740) radioligand binding assay (Fig. 5c) , for mGlu4 and mGlu6 with a [
35 S]GTP␥S binding assay (Fig. 5, d and e), and for mGlu7 with a cAMP accumulation assay (Fig. 5f ). At concentrations up to 10 M CTEP does not show significant activity.
The selectivity profile of CTEP was extended to a total of 103 targets including receptors, enzymes, and ion channels by testing the compound in a CEREP Diversity Profile at a single concentration of 1 M in duplicates and following up targets showing an effect size of Ͼ20% control inhibition with (Table 2; Supplemental Table  S1 ). Taken together, CTEP shows Ͼ1000-fold selectivity for mGlu5 on all targets tested.
Anxiolytic In Vivo Activity of CTEP. CTEP was tested in two paradigms sensitive to antianxiety drugs, the SIH and the Vogel conflict drinking tests. In the former, CTEP was significantly active at doses of 0.1 and 0.3 mg/kg (F 3,34 ϭ 4.9; 0.1 mg/kg, p Ͻ 0.05; 0.3 mg/kg, p Ͻ 0.001) ( Fig. 6a ; all doses oral), whereas only a trend of activity was detected at a dose of 0.03 mg/kg. CTEP did not cause a significant effect on T1 at all doses (data not shown). In the Vogel conflict drinking test, CTEP significantly increased drinking time at doses of 0.3 and 1.0 mg/kg (p Ͻ 0.01), whereas it has no effect at lower doses ( Fig. 6b; all doses oral) . . a, IP accumulation experiments were performed in four (human), eight (mouse), and four (rat) independent experiments in duplicate. b, Ca 2ϩ mobilization experiments were performed in 16 (human), 14 (mouse), and 8 (rat) independent experiments in duplicate. Error bars represent S.E.M.
TABLE 3 CTEP in vitro activity on recombinant human, mouse, and rat mGlu5 in radioligand binding and functional assays
The affinity of CTEP for mGlu5 was determined by recording ͓ 3 H͔CTEP saturation isotherms (Fig. 2, a-c) , and the K i values were measured by ͓ 3 H͔MPEP displacement binding on recombinant mGlu5 expressed in HEK293 cells (Fig. 2d) . IP accumulation and Ca 2ϩ mobilization were tested with HEK293 cells stably (human and rat) or transiently (mouse) transfected with plasmids encoding mGlu5 (Fig. 3) . In radioligand binding experiments, data are mean Ϯ S.E.M. of at least four independent experiments each conducted in triplicate (saturation isotherms) or duplicate (displacement binding). In IP accumulation experiments, data are mean Ϯ S.E.M. of four (human and rat) and eight (mouse) independent experiments each performed in duplicate. In Ca 2ϩ mobilization experiments, data are mean Ϯ S.E.M. of 16 (human), 14 (mouse), and 8 (rat) independent experiments each performed in duplicate. at ASPET Journals on July 9, 2017 jpet.aspetjournals.org
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Pharmacokinetic and Physicochemical Properties of CTEP. The pharmacokinetic properties of CTEP in mice were studied after single and chronic administration. After single oral doses of 4.5 and 8.7 mg/kg CTEP formulated as microsuspension in a saline/Tween vehicle administrated to adult C57BL/6 mice was rapidly absorbed and achieved close to maximal exposure after approximately 30 min (Fig. 7, a and b ; Table 4 ). The half-life of CTEP (oral) was 18 h, and the B/P ratio based on total drug concentrations in plasma and whole brain homogenates was 2.6 (Fig. 7 , a and b; Table 4 ). Chronic administration in adult mice with a dose of 2 mg/kg p.o. every 48 h for 2 months reached a minimal CTEP brain exposure of 240 ng/g (Fig. 8a) . Continuous drug exposure was also achieved in newborn mice when CTEP was administrated every 48 h subcutaneously (Fig. 8b) .
For comparison, the pharmacokinetic profiles of MPEP, MTEP, and fenobam in adult C57BL/6 mice were recorded after oral and intravenous administration (Fig. 7 , c-e; Table  4 ). When dosed orally at 30 mg/kg and formulated as microsuspension (vehicle: 0.9% NaCl and 0.3% Tween 80), MPEP, MTEP, and fenobam were rapidly absorbed with T max ϭ 0.6 h (MPEP) and 0.3 h (MTEP and fenobam). All three compounds showed a rapid in vivo clearance with an estimated half-life of 2 h (MPEP), 0.5 h (MTEP), and 0.3 h (fenobam). The half-life after intravenous administration was estimated as 1.9 h (MPEP), 0.2 h (MTEP), and 0.3 h (fenobam). The ratio between exposure in brain and plasma measured 1 h after a single oral dose of 30 mg/kg was B/P ϭ 0.8 (MPEP), 0.6 (MTEP), and 2.7 (fenobam). The oral bioavailability of CTEP was approximately 100% compared with approximately 6% for MPEP, 7% for fenobam, and 87% for MTEP (Table 4) .
With respect to physicochemical properties, CTEP was moderately lipophilic with an octanol/water distribution coefficient of logD Ͼ4 at pH 7.4. The solubility of CTEP in 50 mM phosphate buffer, pH 6.5 was approximately 1 g/ml at room temperature, and the solubility in dimethyl sulfoxide was Ͼ100 mM. The maximum solubility in artificial cerebrospinal fluid at pH 7.4 achieved with repeated sonication and vigorous shaking was approximately 30 g/ml at 30°C. Based on its chemical properties, the solubility of CTEP in aqueous solution is expected to be pH-dependent with increasing solubility at lower pH. CTEP showed a high plasma protein binding of 99% (mouse plasma; Table 4 ).
In Vivo mGlu5 Brain Receptor Occupancy. The mGlu5 receptor occupancy by CTEP was measured in brain of adult C57BL/6 mice using [ 3 H]ABP688 , a selective mGlu5 antagonist previously used for rodent in vivo binding and human positron emission tomography studies (Ametamey et al., 2007) . CTEP fully displaced [ 3 H]ABP688 in brain regions known to express mGlu5 (Fig. 9) , and 50% displacement was achieved with doses producing an average compound concentration of 77.5 ng/g measured in whole brain homogenate.
Discussion
Pharmacological inhibitors of mGlu5 have been vital for the current understanding of its physiological role in the CNS and enabled clinical research exploring the therapeutic potential of mGlu5 as a drug target in the context of CNSrelated disorders including anxiety, depression, pain, Parkinson's disease, Huntington's disease, and fragile X syndrome (Gasparini et al., 2008; Jaeschke et al., 2008) . The first nonamino acid, selective, and noncompetitive mGlu5 antagonists were 6-methyl-2-(phenylazo)-3-pyridinol (SIB-1757) and (E)-2-methyl-6-(2-phenylethenyl)pyridine (SIB-1893), which inhibited human mGlu5 in IP accumulation assays with moderate potencies of IC 50 ϭ 3.1 and 2.3 M, respectively (Varney et al., 1999) . Structural optimization around these two compounds led to the discovery of MPEP as the first highly potent and selective mGlu5 antagonist with a potency of IC 50 of 36 nM on human mGlu5 (Gasparini et al., 1999) , acting on a specific binding pocket in the transmembrane domain of the mGlu5 receptor involving transmembrane helices 3, 5, 6, and 7 (Pagano et al., 2000; Malherbe et al., 2003) . The discovery of MPEP was a breakthrough because it allowed for the first time the systemic administration of an mGlu5 antagonist with good brain penetration, achieving significant in vivo efficacy in models of pain and anxiety . Further structural optimization led to the identification of MTEP (Cosford et al., 2003) with improved selectivity and bioavailability. The mGlu5 antagonist fenobam was examined for its antianxiety potential in phase II clinical trials in the 1970s, although the molecular target was unknown at the time (Pecknold et al., 1982) . The clinical development of fenobam as an anxiolytic was discontinued because of side effects and erratic bioavailability (Itil et al., 1978; Friedmann et al., 1980) . In 2005, mGlu5 was identified as the drug target of fenobam in a high-throughput screening campaign at F. Hoffmann-La Roche Ltd., and further characterization confirmed fenobam as a potent and selective mGlu5 negative allosteric modulator and potent anxiolytic in animals . Even though structurally diverse, all three tool compounds MPEP, MTEP, and fenobam, act on the same binding pocket at the mGlu5 receptor (Malherbe et al., 2006) .
Here is described CTEP, a novel, potent, and selective orally bioavailable mGlu5 negative allosteric modulator with inverse agonist properties. In saturation analyses, [ (Fig. 2d) , as well as at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Downloaded from mGlu5. The lower potency of CTEP observed in functional assays on mouse compared with human and rat mGlu5, in contrast to the fairly consistent potency of CTEP across all three species in radioligand binding experiments (Table 3) , was unexpected because there are no species differences in the amino acid sequence of the mGlu5 transmembrane regions harboring the presumed binding pocket (Supplemental Fig. S1 ). One possible reason could be the use of transiently transfected cells for mouse mGlu5 as opposed to stably transfected cell lines for human and rat mGlu5 in the functional assays. CTEP suppressed the constitutive activity of mGlu5 in the IP accumulation assay (Fig. 4a) , revealing inverse agonist properties similar to MPEP and fenobam . The allosteric mode of action of CTEP was demonstrated by the rightward shift of agonist concentration-response curves and a simultaneous reduction of the maximal agonist response in the Schild plot (Fig.  4b) (data not shown) . Screening a total of 103 molecular targets, including all known metabotropic glutamate receptors, revealed Ͼ1000-fold selectivity of CTEP for mGlu5.
In vivo, CTEP showed robust pharmacological activity in two models sensitive to antianxiety drugs, the SIH procedure in mice and the Vogel conflict drinking method in rats, with a minimal effective oral dose of 0.1 and 0.3 mg/kg, respectively (Fig. 6) . Compared with fenobam and MPEP, CTEP shows a 30-to 100-fold higher in vivo potency in these procedures Porter et al., 2005) . The in vivo experiments reported here did not reveal any unspecific ef- fects of CTEP such as sedation or general changes in overall health, body temperature, and body weight in a dose range of up to 2 mg/kg. Because of the large differences in the sensitivity of species and test procedures, e.g., for effects of mGlu5 inhibitors on learning and memory (Simonyi et al., 2005) , the possible target-mediated or target-unrelated unspecific effects of CTEP cannot be generally ruled out at this point. Pharmacokinetic studies of CTEP in C57BL/6 mice revealed a high oral bioavailability of approximately 100% and good brain penetration with an average B/P ratio of 2.6 measured as total drug concentrations in plasma and whole brain homogenate, respectively. In this context it is important to note that the reported plasma and brain tissue drug concentrations are not identical to the free fraction of the compound available for binding to the target and do not reflect the subcellular distribution of the drug known to influence its pharmacology (Jong et al., 2009) . These results are in line with CTEP in vivo binding data revealing a 50% displacement of the tracer [
3 H]ABP688 from cortex, hippocampus, and striatum with a dose producing an average drug concentration of 77.5 ng/g in whole brain homogenates and achieving full displacement by a single oral dose of 3 mg/kg (Fig. 9) . One distinctive feature of CTEP is the long half-life of 18 h compared with half-lives of Յ2 h for MPEP, MTEP, and fenobam (Table 4) . On this basis, continuous drug exposure for chronic treatment can be achieved with one dose of CTEP per 48 h in adult and newborn mice (Fig. 8) , whereas the reference compounds MPEP, MTEP, and fenobam would require multiple doses per day. Beyond logistical and cost considerations, long intervals between drug administrations are generally preferred for chronic treatment because the frequent manipulation of animals can affect behavioral and other parameters, alter the basic phenotype (e.g., of transgenic mouse models), and even influence overall well-being and survival. For example, vehicle or sham injections can impair the performance of mice in the elevated plus maze test . Frequent handling of animals can resemble or contribute to enriched environment housing conditions that Fig. 8 . CTEP exposure achieved with chronic dosing in mice. CTEP brain exposure measured in adult (a) and newborn (b) mice after multiple drug administration. CTEP was administered once per 48 h at 0.7 and 2 mg/kg, and brain samples were collected 48 h after dosing. Adult male C57BL/6 mice received CTEP orally, and newborn mice were 2 days old at first dosing and received subcutaneous CTEP injections. Data represent mean of two samples analyzed per time point and experiment. Because exposure was measured 48 h after each administration, data represent the trough (i.e., minimal) exposure levels during the dosing period. at ASPET Journals on July 9, 2017 jpet.aspetjournals.org
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have been reported to profoundly influence an animal's phenotype and behavior, e.g., the increase of synaptic spine density and the elevation of brain-derived neurotrophic factor expression and rate of neurogenesis (Ickes et al., 2000; . Furthermore, enriched environment has been reported to reverse multiple phenotypes in a mouse model of fragile X syndrome , ameliorate impaired learning and memory performance in a mouse model of Down syndrome (Martínez-Cué et al., 2002) , and delay the loss of dopaminergic neurons in models of Parkinson's disease (Faherty et al., 2005) . On this background, the use of drugs with a long half-life such as CTEP allowing the least dosing frequency for chronic treatment offers advantages especially when dealing with fragile or very young animals and with phenotypes or parameters sensitive to enriched environment. Taken together, CTEP represents a novel, potent, and selective orally bioavailable mGlu5-negative allosteric modulator with inverse agonist activity, and it represents the first mGlu5 inhibitor with a long half-life. By enabling long duration treatments through a wide age range, CTEP is expected to make an important contribution to the efforts of exploring the full therapeutic potential of mGlu5 inhibitors for indications such as Parkinson's disease and depression and for neurodevelopmental disorders including fragile X syndrome and autism. Fig. S1: Amino acid sequence alignment of human, rat and mouse mGlu5a.
The three mlu5a orthologues share an overall amino acid sequence identity of 94.7%. With the exception of one conservative amino acid change at position 600, the sequence of the transmembrane regions harboring the MPEP binding pocket (highlighted in green) is identical in all three species. Transmembrane regions are indicated as TM1-7; amino acid positions identified as part of the MPEP binding pocket according to Malherbe et al. (2003) are highlighted in green, amino acid sequence differences are highlighted in yellow, non-conservative sequence differences are highlighted additionally with red letters (non-conservative: Sequence differences between instead of within groups of amino acids with similar properties, i.e. hydrophilic acidic, hydrophilic basic, polar uncharged, and hydrophobic amino acids).
